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Expression and autoregulation of transforming growth factor /B receptor
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Summary In small-cell lung cancer cell lines resistance to growth inhibition by transforming growth factor
(TGF)-f,, was previously shown to correlate with lack of TGF-,B receptor I (RI) and II (RII) proteins. To
further investigate the role of these receptors, the expression of mRNA for RI, RII and beta-glycan (RIII) was
examined. The results showed that loss of RII mRNA correlated with TGF-3,B resistance. In contrast, RI- and
beta-glycan mRNA was expressed by all cell lines, including those lacking expression of these proteins.
According to Southern blot analysis, the loss of type II mRNA was not due to gross structural changes in the
gene. The effect of TGF-fl, on expression of TGF-,B receptor mRNA (receptor autoregulation) was examined
by quantitative Northern blotting in four cell lines with different expression ofTGF-fl receptor proteins. In two
cell lines expressing all three TGF-fl receptor proteins beta-glycan mRNA was rapidly down-regulated and this
effect was sustained throughout the 24 h observation period. RI and RII mRNAs were slightly increased 24 h
after treatment. In one cell line sensitive to growth inhibition by TGF-fi,, but lacking beta-glycan expression,
and one cell line expressing only beta-glycan and thus TGF-f,B-resistant, no autoregulation of mRNA of either
TGF-,B receptor was demonstrated. The results suggest that TGF-fl, regulates the expression of its receptors, in
particular beta-glycan, and that this effect is dependent on co-expression of beta-glycan, RI and RII.
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factor beta receptor mRNA; autoregulation
Transforming growth factor /B (TGF-fl) is the prototype
polypeptide growth factor of the TGF-,B superfamily, which
also includes e.g. the activins, inhibins and bone morphoge-
netic protein (Massague, 1990). TGF-# acts in a paracrine
and autocrine fashion as a multifunctional growth factor,
influencing basic cellular functions such as proliferation,
differentiation, cell-cell and cell-matrix interaction (Roberts
and Sporn, 1990; Moses, 1992; Kingsley, 1994). Three
isoforms TGF-/,3, TGF-f32 and TGF-/33, are expressed by
many human cell types; TGF-3,B is the most widely studied.
In mammalian cells the TGF-# isoforms bind with high
affinity and specificity to three transmembrane receptors (type
I, II and beta-glycan), which are expressed by a wide range of
normal and malignant cells (Attisano et al., 1994; N0rgaard
et al., 1995).
Type I (RI) and type II (RII) receptors are structurally
analogous glycoproteins with an intracellular serine/threonine
kinase domain. They are considered to be the signal-
transducing TGF-# receptors, as both receptors are required
for mediating the various effects of TGF-,B (Wrana et al.,
1992, 1994).
TGF-,B, has a strong growth inhibitive effect in vitro on
most ectodermally derived cell types (N0rgaard et al., 1995).
In small-cell lung cancer (SCLC) cell lines, resistance to
growth inhibition by TGF-f,, correlated with lack of RI and
RII protein (N0rgaard et al., 1994), and in other human
cancer cell lines with decreased or loss of RII protein
expression (Geiser et al., 1992; Inagaki et al., 1993; Park et
al., 1994). Very recently it was described that in colon cancer
cell lines loss of RII mRNA and protein owing to mutations
within small repeated sequences of the RII gene correlated
with DNA repair defects (Markowitz et al., 1995). The role
of RI expression is less defined due to the fact that this
receptor only binds TGF-,B in the presence of RII (Laiho et
al., 1991; Inagaki et al., 1993). Hence, RI cannot be detected
by ligand-binding assays (e.g. chemical cross-linking assay)
unless co-expressed with RII. Recently, cDNAs for human
RI and RII were cloned. Several different human RI receptor
cDNAs were identified (Attisano et al., 1993; Franzen et al.,
1993; ten Dijke et al., 1994). Some of these had the capacity
to bind the different members of the TGF-,B superfamily,
depending on the type of RII with which they were co-
expressed (Ebner et al., 1993a; Attisano et al., 1993; ten Dijke
et al., 1994). However only one RI, termed ALK-5, has been
shown to respond to TGF-1l3 binding with serine/threonine
kinase activity and to restore TGF-f, response upon
transfection into RI-defective cells (Franzen et al., 1993). In
contrast to RI, only one RII has been found (Lin et al.,
1992).
Beta-glycan, also termed type III TGF-# receptor, is a
proteoglycan, which is structurally different from the type I
and II receptors. It has a relatively large extracellular part,
and a short cytoplasmic part, which apparently lacks a
catalytic domain (Lopez-Casillas et al., 1991; Wang et al.,
1991; Moren et al., 1992). Accordingly several cell types are
responsive to TGF-,B despite lacking beta-glycan (Wang et
al., 1991; Boyd and Massague, 1989; N0rgaard et al., 1994;
Lopez-Casillas et al., 1993), but in some cases the presence of
beta-glycan in these cells increased the binding of TGF-f to
RII. Beta-glycan is therefore thought to function as a ligand
capacitor, regulating the amount of ligand available for the
signalling receptors RI and RII.
TGF-f3, may exert its growth-inhibitory effect in part by
regulating the expression of other polypeptide growth factors
and their receptors (Assoian et al., 1984; Massague, 1985).
TGF-13, was also shown to induce its own expression (Van
Obberghen-Schilling et al., 1988), but whether the expression
of TGF-,B receptors is regulated by TGF-3,B (autoregulation)
has not yet been described.
In this study we characterised the expression of mRNA for
RI (ALK-5) and RII and beta-glycan in a panel of nine
SCLC cell lines previously examined for TGF-J,A sensitivity
(N0rgaard et al., 1994) and with different expression of TGF-
# receptor proteins (Damstrup et al., 1993). In addition, we
studied autoregulation of TGF-,B receptor mRNA in four of
the cell lines, by quantitating the effect of exogenous TGF-3,B
on the expression of these mRNAs.
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The results showed an unequivocal correlation between
expression of RII mRNA and sensitivity to growth
inhibition by TGF-/31, whereas all cell lines expressed RI
and beta-glycan mRNA, regardless of whether these receptor
proteins were expressed. According to Southern blot analysis
lack of RII mRNA was not due to gross structural changes
in the gene encoding this receptor. TGF-,B receptor mRNA
was autoregulated in two cell lines expressing all three
receptor proteins. Beta-glycan mRNA was rapidly down-
regulated, whereas RI and RII mRNAs were subsequently
increased 2- to 3-fold. In one cell line expressing RI and RII
proteins but not beta-glycan, and thus still sensitive to
growth inhibition by TGF-f,, and one TGF-f,B-resistant cell
line expressing only beta-glycan, TGF-# receptor mRNA
expressions were practically unaffected by TGF-fl,. Auto-
regulation of beta-glycan mRNA autoregulation was
partially antagonised by addition of cycloheximide, indicat-
ing that de novo protein synthesis was to some extent
required for this effect. The results suggest that TGF-#
receptor autoregulation is dependent on expression of an
'intact' receptor system, and thus provides an example of a
functional interaction between RI, RII and beta-glycan, not
previously described.
Materials and methods
Cell lines
SCLC cell lines were cultured in 525 cm2 triple flasks
(NUNC) at 37°C, 5% carbon dioxide and 80% humidity in
medium containing 10% inactivated (56°C, 30 min) fetal calf
serum (Flow Laboratories, Irvine, UK) without antibiotics.
Nine SCLC cell lines established from six patients, and
characterised as SCLC cell lines in three different labora-
tories, were examined. Four cell lines established at Dart-
mouth Medical School, Hanover, NH, USA (DMS 53,
DMS 92, DMS 114, DMS 273) (Pettengill et al., 1980;
Sorenson et al., 1984) were cultured in Waymouth medium
(Gibco, Paisley, UK). Three cell lines established at
Groningen Lung Cancer Center, Groningen, The Nether-
lands (GLC 3, GLC 16, GLC 19) (Berendsen et al., 1988; De
Leij et al., 1985) were cultured in RPMI-1640 (Gibco) and
two cell lines established in our laboratory (CPH 54A,
CPH 54B) (Engelholm et al., 1986) were grown in EMEM
(Eagle's minimum essential medium) (Gibco). The cells were
passaged twice a week. Cells growing as monolayer cultures
(CPH 54A, CPH 54B, DMS 53, DMS 92, DMS 114,
DMS 273) were passaged with trypsin. Cells growing as
floating aggregates (GLC 3, GLC 16, GLC 19) were allowed
to sediment before replacing the medium.
All cell lines were routinely checked for, and found free of,
mycoplasma infection.
For steady-state mRNA expression studies subconfluent,
exponentially growing cells were harvested using a cell
scraper and centrifuged at 1100 g. The cell pellet was frozen
immediately in liquid nitrogen and stored at -70°C until
analysis.
Growth factor treatment assay
Porcine TGF-/, was purchased from R&D Systems Europe,
Oxon, UK. Dried TGF-/3, (1 pg) was reconstitued in 0.5 ml
of 4 mm hydrochloric acid containing 2 mg ml-' bovine
serum albumin and stored at 4°C. For treatment assays,
culture medium (with 10% fetal calf serum) containing
400 pM TGF-f,B was made immediately before each experi-
ment.
Exponentially growing cells were harvested as described
above, resuspended in PBS and centrifuged at 275 g for
5 min. Single cell suspension was obtained by mechanical
disaggregation. Cells were counted in a haemocytometer and
viability was evaluated by the trypan blue exclusion test.
Approximately 5x 106 viable cells were seeded in 175 cm2
culture flasks.
Cells were treated with TGF-,B, as previously described
(N0rgaard et al., 1994). Briefly, cells growing as monolayer
cultures were allowed to attach for 24 h. Culture medium was
removed from the subconfluent cells and prewarmed (37°C)
medium+400 pM TGF-fl was added (designated T=0 h).
Cells growing as floating aggregates were seeded directly in
prewarmed (37°C) medium+400 pM TGF-3,I (T=0 h). After
1, 2, 4, 8 and 24 h treated cells and untreated cells (control)
were harvested as described above. All experiments were
reproduced at least twice.
Cycloheximide treatment
Where indicated, 10 jug ml-1 cycloheximide (Sigma, St Louis,
MO, USA) dissolved in PBS was added to the culture
medium alone or in combination with TGF-,B,, and cells were
harvested as described above after 4 and 24 h.
RNA extraction, electrophoresis and blotting
PolyA+ RNA as extracted directly from the frozen (-70°C)
cell pellets by the guanidinium thiocyanate method followed
by two sequential purifications by oligo(dT)-cellulose
chromatography using a commercial kit (QuickPrep
mRNA Purification Kit, Pharmacia) (Chirgwin et al.,
1979). The concentration was determined by spectrophoto-
metry, and the RNA was precipitated under ethanol at
- 70°C, in aliquots of 3-5 pg. The RNA was dissolved in
sample buffer (50% formamide, 2.2 M formaldehyde, 20 mM
3-morpholino-propane-sulphonic acid, 5 mm sodium acetate,
1 mM EDTA, 2% Ficoll 400, 0.25% bromophenol blue)
containing 0.033 g pl-' ethidium bromide and electrophor-
esed under denaturing conditions in 1% agarose gels
containing 2.2 M formaldehyde, together with 5 pg RNA
size marker (RNA ladder, Gibco BRL). Transfer to charged
nylon membranes (Gene Screen Plus, NEN DuPont) was
done in 10 x saline sodium citrate (1 x saline sodium ci-
trate= 150 mm sodium chloride, 15 mM sodium citrate). The
Northern blots were prehybridised for at least 3 h and
hybridised for 18 h at 42°C in a buffer containing 50%
formamide, 1% sodium dodecylsulphate, 1 M sodium
chloride, 5% dextran sulphate, 100 pg ml-' denatured
salmon testes DNA. Maximal washing stringency was
65°C in 2 x saline sodium citrate, 1% sodium dodecylsul-
phate.
For determination of steady-state mRNA expression
Northern blots were exposed to X-ray film (Amersham) at
- 80°C with an intensifying screen for 1-7 days. The blots
were hybridised and rehybridised with the three TGF-,B
receptor probes, followed by the glyceraldehyde-3 phosphate
dehydrogenase (GAPDH) probe, which was used as an
internal standard to compare the amounts of polyA+ RNA
transferred to the membranes.
RNA quantification
In order to minimise loss of mRNA from the membranes
during the high stringency wash performed to strip off the
probes, Northern blots for quantitative measurements were
used for only one hybridisation with a TGF-,B receptor probe
and subsequently reprobed with the GAPDH standard probe.
The hybridised Northern blots were analysed on a
phosphorimager (Molecular Dynamics). The amounts of
receptor mRNA were normalised against the corresponding
amounts of GAPDH mRNA, which was found to be
unaffected by TGF-fl1 (Edwards et al., 1985). The normal-
ised amounts ofTGF-fB receptor mRNA in cells treated with
TGF-,B, were expressed relative to the respective mRNA
amounts of the corresponding untreated cells (per cent of
control). The differences in expression levels were evaluated
by the Student's t-test (significance level; P<0.05). After
phosphorimager analysis autoradiography of the blots as
performed as described above, with the purpose of photo
reproduction.TGF-p receptor mRNA in SCLC
P N0rgaard et al 0
1039
DNA extraction, electrophoresis and blotting
DNA was extracted with phenol and chloroform by standard
methods (Sambrook et al., 1989). Digestion with restriction
endonucleases BamHI or PstI was performed as recom-
mended by the supplier (Gibco BRL, Life Technologies
Europe). Aliquots of 10 ig/lane were electrophoresed in
0.8% agarose gels and transferred to charged nylone
membranes (Gene Screen Plus, NEN DuPont). Prehybridisa-
tion, hybridisation and washing were as recommended by the
supplier: washing stringency was 2 x saline sodium citrate-
1% sodium dodecylsulphate twice for 30 min at 60°C.
Southern blots were reprobed with a human GAPDH
probe. Membranes were exposed to X-ray film (Amersham)
at -80°C with an intensifying screen for 7 days.
Probes
Two RI probes were used. One was a 960 bp EcoRI fragment
of the cloned 2.3 kb ALK-5 human cDNA kindly provided
by K Miyazono (Franzen et al., 1993). The other was the full
length (2.4 kb EcoRI insert) Tsk-7L murine cDNA kindly
provided by R Ebner (Ebner et al., 1993b). The RII probe
was a 930 bp PstI-SacI fragment of the cloned 4.5 kb H2-
3FF human cDNA kindly provided by HY Lin (Lin et al.,
1992). The probe for beta-glycan was a 1.1 kb PstI fragment
of the cloned 4.2 kb TIIIR-2 human cDNA kindly provided
by K Miyazono (Moren et al., 1992). The human GAPDH
probe was a 1.1 kb cDNA fragment purchased from
Clontech (Palo Alto, CA, USA), hybridising to a 1.4 kb
mRNA. Isolation of cDNA probes was done by standard
methods (Sambrook et al., 1989). Radiolabelled probes were
prepared by the random priming method (Feinberg and
Vogelstein, 1983) using a commercial kit and [x_-32P]dCTP
(both from Amersham).
Results
Steady-state TGF-,B receptor mRNA expression
The steady-state expressions of TGF-,B receptor mRNA of
the examined SCLC cell lines were analysed by Northern
blotting. All nine cell lines expressed a single
- 6.5 kb RI
mRNA (ALK-5) and a single
- 7.0 kb mRNA for beta-
glycan, whereas only six cell lines expressed a
- 5.5 kb RII
mRNA (Figure 1).
Effect of TGF-f, on TGF-,B receptor mRNA levels
The effect of TGF-/,1 on the expression of TGF-,B receptor
mRNA over a 24 h period was examined by quantitative
Northern blot analysis in four SCLC cell lines with different
TGF-f,3 sensitivity and receptor protein expression: CPH 54A
and CPH 54B, GLC 19, GLC 3.
CPH 54A and 54B express all three TGF-,B receptors at
the mRNA and protein levels (Figure 1 and Table I).
Treatment of these cell lines with TGF-/,3 resulted in a
statistically significant increase in expression of RI and RII
mRNA detected after 24 h of treatment (Figures 2 and 3). RI
mRNA was increased approximately 3-fold, whereas RII
mRNA was increased about 2-fold compared with control
levels. The responses were very similar in the two cell lines.
CPH 54A and 54B also expressed mRNA for another RI,
Tsk-7L (Ebner et al., 1993b), which is the murine homologue
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Southern blotting
The SCLC cell lines were examined for gross structural DNA
changes of the RII gene. Southern blots of genomic DNA
digested with BamHI or PstI were hybridised with the RII
probe. No absent or abnormal bands were detected in the
three SCLC cell lines lacking RII mRNA expression
(DMS 114, DMS 92, GLC 3) compared with the six cell
lines expressing RII mRNA (data not shown).
Figure 1 Northern blot anlaysis of TGF-,B receptor I, II and
beta-glycan mRNA in nine SCLC cell lines. PolyA+ RNA (3-
5pl/lane) were electrophoresed in formaldehyde gel, transferred to
nylon membranes and subsequently hybridised with the human
TGF-,B receptor probes: type I (ALK-5), type II (H2-3FF), beta-
glycan (TIIIR-2). The membranes were reprobed with the
GAPDH probe, as an internal standard, to compare the amount
of RNA transferred to the membranes. rI, type I receptor; rII,
type II receptor.
Table 1 Expression ofTGF-,B receptor type I, II and beta-glycan mRNA and protein, and in vitro sensitivity to growth inhibition byTGF-f,,
in nine SCLC cell lines
TGF-fl-r mRNA TGF-fl-r proteina TGF-fl, growth
Cell line I II BG I II BG inhibitionb
CPH 54A + + + + + + +
CPH 54B + + + + + + +
GLC 16 + + + + + +
GLC 19 + + + + + +
DMS 273 + + + + (+) + +
DMS 53 + + + (+)
DMS 114 + + +
GLC 3 + + +
DMS 92 + + NT
aExamined by chemical cross-linking assay. Data from Damstrup et al. (1993)."Data fromN0rgaard et al. (1994). BG, beta-glycan (type III
receptor); NT, not tested. Parenthesis indicates weak type II receptor expression and weak growth inhibition respectively.TGF-,B receptor mRNA in SCLC
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Figure 2 Northern blot analysis of TGF-,B receptor I, II and
beta-glycan mRNA in the SCLC cell line CPH 54B treated with
TGF-fJ1. The cells were grown for the indicated time in the
presence (+) or absence (-) of 400pM TGF-,B. PolyA+ RNA
(3-5yg/lane) were electrophoresed in formaldehyde gel, trans-
ferred to nylon membranes, and hybridised with one of the
human TGF-,B receptor probes: type I (ALK-5), type II (H2-
3FF), beta-glycan (TIIIR-2). The membranes were stripped and
reprobed with the GAPDH probe (internal standard), to compare
the amount of RNA transferred to the membranes. rI, type I
receptor; rII, type II receptor.
of the human ALK-2 receptor. Tsk-7L cDNA, which
hybridised to a -3.3 kb mRNA, was increased by TGF-j31
in a manner similar to ALK-5, i.e. 3-fold increase after 24 h
treatment (data not shown).
In contrast to RI and RII beta-glycan mRNA in CPH 54A
and 54B was reduced by TGF-f,B (Figures 2 and 3). The
reduction 4 h after treatment was more pronounced in
CPH 54B than in 54A, but in both cell lines maximal
inhibition was 30-40% of the level of untreated cells. The
inhibition of beta-glycan mRNA was sustained throughout
the 24 h observation period (Figures 2 and 3).
GLC 19 lacks beta-glycan expression at the protein level,
but expresses mRNA for all three receptors, and GLC 3
expresses only beta-glycan at the protein level (Table I).
When these cells were treated with TGF-fl1, no statistically
significant modulation of TGF-,B receptor mRNA was
observed. In GLC 19 RII mRNA showed a slight decreasing
tendency, which was, however, not statistically significant
throughout the experiment (Figure 3). As indicated with
asterisks in Figure 3 minor changes in RII mRNA expression
in CPH 54A, 54B and GLC 19 were observed during the first
8 h, and a slight decrease in beta-glycan expression was seen
in GLC 3. The limited magnitude and extension of these
changes, however, suggest that they represent methodological
artefacts.
Effect of cycloheximide on beta-glycan mRNA level
To test whether protein synthesis was required for the
observed down-regulation of the beta-glycan mRNA level
(Figure 3), CPH 54A was incubated for 4 or 24 h with
cycloheximide (10 jug ml-') alone or in combination with
400 pM TGF-p1. Quantitative Northern blot analysis showed
that cycloheximide by itself reduced beta-glycan mRNA, but
in a less pronounced way than TGF-fi, after 4 h treatment
(Figure 4). Four hours' cycloheximide treatment antagonised
the TGF-fl1 effect. After 24 h cycloheximide markedly
reduced beta-glycan mRNA both alone and in combination
with TGF-13l.
Discussion
We previously found that sensitivity to the growth-inhibitory
effect of TGF-fl, correlated with expression of RI and RII
proteins, in a panel of nine SCLC cell lines (N0rgaard et al.,
1994). TGF-f receptors in these cell lines were determined by
chemical cross-linking of radiolabelled TGF-fl, (Damstrup et
al., 1993), and as RI only binds TGF-fJ1 when co-expressed
with RII (Laiho et al., 1991; Inagaki et al., 1993), these data
could not exclude the possibility that some of the 'RII-
negative' cell lines in fact expressed RI.
We therefore studied the expression of mRNA for the
TGF-f5 receptors in the panel of SCLC cell lines, and found a
correlation between expression of RII mRNA and sensitivity
to TGF-fl, (Table I). RI and beta-glycan mRNAs were
expressed by all cell lines examined, including the cell lines in
which these receptor proteins were not detected (Table I),
thus there was no correlation between expression of RI or
beta-glycan mRNA and sensitivity to growth inhibition by
TGF-fl, (Table I). These results emphasise the role of RII as
determinant for TGF-fi-sensitivity in SCLC. There was a
correlation between expression of RII mRNA and protein
except for one cell line, DMS 53, in which the protein was
not detected (Damstrup et al., 1993) (Table I). DMS 53 was
earlier found to respond weakly to TGF-#,, and we
concluded that RII protein was expressed below the
detection limit of the chemical cross-linking assay (N0r-
gaard et al., 1994).
Previously only three reports have described the genetic
background for loss of RII in human cancer cells. In one
study a panel of colon cancer cell lines was found to
harbour mutations in the RII gene, resulting in absent or
low levels of RII transcripts and resistance to TGF-,B growth
inhibition (Markowitz et al., 1995). There was a highly
significant correlation between escape from the growth-
inhibitive effect of TGF-j and microsatellite instability
resulting in DNA repair defects. In gastric cancer cell lines
(Park et al., 1994) and human T-cell malignancy (Kadih et
al., 1994) TGF-# resistance was likewise due to altered RII
mRNA, caused by amplifications or deletions of the RII
gene. Our demonstration of lack of RII mRNA as the cause
of TGF-1l3 resistance in SCLC, together with the finding
that 16/21 SCLC cell lines lack RI and RII proteins
(Damstrup et al., 1993), add to an emerging picture of a
frequent defect of importance in growth regulation in
cancer. In agreement with this, we found no signs of
deletion or translocation of the RII gene by Southern
blotting (data not shown), indicating that the lack of RII
mRNA in SCLC could be due to point mutations or
silenced transcription.
For RI and beta-glycan we demonstrated a discrepancy
between mRNA and protein expression (Table I). This opens
the possibility that RI protein was in fact expressed by the
'RII-negative' cell lines, but inaccessible to detection by the
chemical cross-linking assay, as earlier demonstrated in
human hepatoma cell lines (Inagaki et al., 1993) and mink
lung cells (Laiho et al., 1991). Four cell lines expressed beta-
glycan mRNA despite lack of beta-glycan protein expression
(Table I). We could conclude that no deletion or
translocation of the beta-glycan gene had occurred in these
cell lines, since they all expressed a -7.0 kb transcript
(Figure 1), and Southern blot analysis showed no evidence of
structural changes in the gene (data not shown). The only
previous characterisation ofbeta-glycan mRNA expression in
human cancer cells was done on the human gastric carcinomaTGF-,B receptor mRNA in SCLC
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Figure 3 The effect of TGF-,13 on expression of TGF-fl receptor mRNA in four SCLC cell lines. PolyA+ RNA as extracted from
cells treated for the indicated time with 400pM TGF-fl1 or with no additions (control). Northern blots were prepared, hybridised
with one of the human TGF-13 receptor probes and quantified on a phosphorimager. The blots were stripped, reprobed with the
GAPDH probe (internal standard), and quantified. The level of expression in treated cells was normalised to the level in the
corresponding control cells and expressed as per cent of control. Bars represent mean values of at least two separate
experiments+s.d. *Significant difference (P<0.05, Student's t-test). rI, type I receptor; rll, type II receptor. El1, untreated; *,
treated with TGF-/31.
cell lines described above. In contrast to our findings, they
demonstrated a variable pattern of beta-glycan mRNA
expression (Park et al., 1994).
In regulating cell growth, TGF-# operates in an autocrine
and paracrine fashion as part of a dynamic network
including other growth factors (Aaronson, 1991). TGF-fl,
modulates the expression of a number of these growth
factors and their receptors, e.g. epidermal growth factor
(Assoian et al., 1984; Massague, 1985), platelet-derived
growth factor (Leof et al., 1986; Win et al., 1993) and
fibroblast growth factor (Kikuchi et al., 1992). In addition,
TGF-/31 was shown to increase, i.e. autoregulate, its own
expression (Van Obberghen-Schilling et al., 1988). As
control of TGF-,B receptor expression determines cellular
responsiveness to TGF-fi1, we wanted to examine whether
TGF-,B receptor expression was also autoregulated. In this
study we used quantitative Northern blotting to demonstrate
autoregulation of RI, RII and beta-glycan mRNAs in two
cell lines, CPH 54A and 54B, which expressed all three
receptor proteins (Table I). In two cell lines, GLC 19,
expressing only RI and RII proteins, and GLC 3 expressing
only beta-glycan, autoregulation of TGF-,B receptor mRNA
could not be demonstrated (Figure 3).
TGF-,B receptor autoregulation observed in CPH 54A and
54B (Figure 3) followed a distinct pattern, where beta-glycan
expression was reduced after 4 h and throughout the 24 h
treatment period followed by a slight increase of RI and RII
expression after 24 h.
Beta-glycan is dispensable for mediation ofTGF-j31 growth
inhibition in many cell types including SCLC (N0rgaard et al.,
1994), but apparently plays a role for binding ofTGF-,B to RII
(Wang et al., 1991; L6pez-Casillas et al., 1993). In CPH 54A
and 54B beta-glycan provides more than 75% of the TGF-3,B
binding sites (unpublished data). Considering that observed
mRNA down-regulation is reflected at the protein level, it
would have a considerable impact on cellular TGF-/3, binding,
towards a net decline in ligand available for the signalling
receptors. We in fact observed a decline in TGF-fl, binding in
CPH 54A, when this cell line, which expresses high levels of
TGF-,B,, was allowed to condition the culture supernatant for
more than 2 days (unpublished data).
Co-treatment of CPH 54A with the protein synthesis
inhibitor cycloheximide reduced the TGF-3, effect on beta-
glycan mRNA (Figure 4), indicating that beta-glycan
autoregulation was to some extent dependent on de novo
protein synthesis. This observation, together with the time
course, suggests that the regulation was executed at the post-
transcriptional level.
The increase of RI and RII mRNA seen at the end of the
24 h observation period could reflect a consumption of
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Figure 4 Quantitativ-e Northern blot analI-sis of the effect of
cvcloheximide alone or in combination with TGF-fl1 on beta-
gI-can mRNA in the SCLC cell line CPH 4A. PolvA RNA as
extracted from cells treated for 4h or '4h with no additions
(control). with 4OOpNi TGF-f3. with 10pa ml- cvcloheximide
and their combination. Northern blots A-ere prepared. hvbridised
with the beta-glI-can probe and quantified on a phosphorimager.
The blots were stripped. reprobed with the GMPDH probe
(internal standard). and quantified. The level of expression in
treated cells w-as normalised to the level in the corresponding
control cells. and expressed as per cent of control. Bars represent
mean values of three separate Northern blots-s.d. CHX.
c-cloheximide.
signalling receptors. However. despite the fact that the assay
used is sensitive and the increases in mRNA expression w-ere
statisticall1 significant. the biological meaning of this
observation is uncertain because of the limited degree of
expression induction. However. autoregulation of a type I
TGF-# receptor has also been demonstrated recently in
human hepatoma cell lines (Inagaki et al.. 1994). It was
shown that the expression of an RI (SKR-1) was rapidly and
stronglv increased, whereas RII mRNA was unaffected bv
TGF-#1. The autoinduction of this RI. which is the human
homologue of Tsk-7L and capable of binding both TGF-f
and activin. agrees with our findings in SCLC The different
findings concerning RII autoregulation could be explained by
differences in the assays employed. Quantification of receptor
mR,NA in the hepatoma cell line was performed by visual
interpretation of Northem blots of total RNA. This method
is less sensitive than the phosphorimager analysis of blots of
polvA- selected RNA used in the present study.
Our data suggest that TGF-fl, regulates the expression of
its own receptors. in particular beta-glycan. and that this
autoregulation is dependent on expression at the protein level
of both beta-glycan. and the signalling receptors RI and RII.
This was supported by the finding that TGF-f receptor
mRNAs were not autoregulated in GLC 19. despite the fact
that this cell line had previously been shown to be sensitive to
growth inhibition by TGF-1i3 (N0rgaard et al.. 1994) and to
express TGF-13, (unpublished data).
Ligand-induced complex formation betw-een RI and RII
and beta-glycan has been demonstrated in other cell types
(L6pez-Casillas et al.. 1993: Inagaki et al.. 1993; Moustakas
et al.. 1993: Yamashita et al.. 1994). and the present
demonstration of interdependent receptor autoregulation
could represent a functional extension of these data.
Abbreviations
GAPDH; lx-ceraldehyde-3 phosphate dehydrogenase: SCLC.
small-cell lung cancer: TGF-f. transforming growth factor f.
Acknowledgements
The authors thank Dr Kohei Mivazono for the ALK-5 and TIIIR-
2 cDN-As. Dr Reinhard Ebner for the Tsk-7L cDN-A and Dr
Herbert Lin for the H2-3FF cDN-A. Dr Jens Hoirlis-Nielsen.
Hagedorn Research Institute is thanked for providing access to the
phosphorimager. The technical assistance of Jette Rohrmann and
Charlotte Jespersen and the photographic serv-ice of Bent Borgesen
are gratefully acknowledged. This study was supported by grants
from the Leo Nielsen Foundation. the Danish Cancer Research
Foundation. the Einar Willumsen Memorial Foundation. The
Danish Research Academyn and the Danish Medical Research
Council.
References
AARONSON SA_ (1991). Growth factors and cancer. Science. 254.
1 146 - I 153.
ASSOIAN RK. FROLIK CA. ROBERTS AB. MILLER DM AND SPOR-N
MB. (1984). Transforming growxth factor-f controls receptor levels
for epidermal growth factor in NRK fibroblasts. Cell. 36, 35-41.
ATTISANO L. CARCAMO J. V'EN-TURA F. WEIS FMB. MASSAGUE J
AND A-RANA JL.( 1993). Identification of human activin and
TGFfl type I receptors that form heterodimeric kinase complexes
w-ith type II receptors. Cell. 75. 671 -680.
ATTISANNO L. AWR_-NA JL. LOPEZ-CASILLAS F AND MASSAGUE J.
(1994). TGF-3 receptors and actions. Biochim. BiophYs. .4cta.
1222, 71-80.
BERENDSEN HH. DE LEIJ L. DE *'RIES EGE. MESANDER G.
NMULDER N-H. DE JONG B. BUY'S CHCMN. POSTMIUS PE. POPPEMA
S. SLUITER HJ AN-D THE HT. (1988). Characterization of three
small cell lung cancer cell lines established from one patient
during longitudinal follow-up. Cancer Res.. 48. 6891 -6899.
BOYD FT AN-D MASSAGUE J. (1989). Transforming growth factor-f
inhibition ofepithelial cell proliferation is linked to the expression
of a 53-kDa membrane receptor. J. Biol. Chem.. 264, 227 -2278.
CHIRGWIN- J-X. PRZY'BY'LA AE. MACDONALD RJ A'ND RUTTER W-J
(1979). Isolation of biolo icallv active ribonucleic acid from
sources enriched in ribonuclease. BiochemistrY. 18, 5294-5299.
DAMSTRUP L. RYGAARD K. SPAN-G-THOMSEN M AND POULSEN
HS. ( 1993). Expression ofthe transforming growth factor fi (TGF-
fl) receptors and TGF-fl. TGF-f2. and TGF-f3 in human small
cell lung cancer cell lines. Br. J. Cancer. 67, 1015- 1021.
DE LEIJ L. POSTMUS PE. BUYS CHCMN. ELEMNA JD. RAMAEKERS F.
POPPEMA S. BROUWER M. VAN DER VEENN AY. MESANDER G
AND THE TH. ( 1985). Characterization of three new variant type
cell lines derived from small cell carcinoma of the lung. Cancer
Res.. 45, 6024-6033.
EBNNER R. CHEN R-H. LAW-LER S. ZION'CHECK T ANrD DERYNNCK R.
(l993a). Determination oftyIpe I receptor specificity by the ty-pe II
receptor for TGF-fl or activin. Science. 262. 900-902.
EBN'ER R. CHEN R-H. SHIUM L. LAW'LER S. ZION-CHECK TF. LEE A.
LOPEZ AR AND DERYNCK R. (1993b). Cloning ofa type I TGF-fl
receptor and its effect on TGF-# binding to the type II receptor.
Science. 260, 1344- 1348.
EDW'ARDS DR. PARFETT CL A-ND DENHARDT DT. (1985).
Transcriptional regulation of two serum-induced RNAs in
mouse fibroblasts: Equivalence of one species to B2 repetitiVe
elements. tfol. Cell. Biol.. 5, 3280-3288.
EN-GELHOLM SA. SPANG-THOMSENT M. VIN-DELOV LL. BRIUNNNER
N. NIELSEN MH. HIRSCH F AND HANSEN HH. (1986).
Comparison of characteristics of human small cell carcinoma of
the lung in patients. in vitro and transplanted into nude mice.
.Acta Pathol. Mticrobiol. Scand. Sect. A Pathol.. 94, 325-336.
FEINBERG AP AND VOGELSTEIN- B. (1983). A technique for
radiolabeling DNA restriction endonuclease fragments to high
specific activity. Anal. Biochem.. 132 6 - 13.TGF-3 receptor mft4A in SCLC
P Norgaard et al M
1043
FR_NZEN P. TEN DIJKE P. ICHIJO H. Y'ANIASHITA H. SCHULZ P.
HELDIN C-H A'ND MIYAZON-O K. (1993). Cloning of a TGF-/
type I receptor that forms a heteromeric complex w-ith the type II
receptor. Cell. 75. 681 -692.
GEISER AG. BURMNIESTER JK. WEBBIN'K R. ROBERTS AB AND
SPORN NIB. (1992). Inhibition of growth by transforming growth
factor-/3 following fusion oftwo nonresponsi-e human carcinoma
cell lines. J. Biol. Chem.. 267, 2588 -2593.
INAGAKI NM. MOUSTAK_S A. LIN HY. LODISH HF AND CARR BI.
( 1993). Growth inhibition by transforming growth factor /3 (TGF-
/ ) tvpe I is restored in TGF-/3-resistant hepatoma cells after
expression of TGF-# receptor type II cDN-A. Proc. Nat! Acad.
Sci. LS-4. 90., 359-5363.
INAGAKI M. W'A-NG ZQ AND CARR BI. (1994). Transforming growth
factor beta 1 selectively increases gene expression of the serine
threonine kinase receptor 1 (SKRl (in human hepatoma cell lines.
Cell Struct. Funct.. 19, 305-313.
KADIN ME. CACAILLE-COLL MW. GERTZ R. NMASSAGUE J.
CHEIFETZ S AND GEORGE D. (1994). Loss of receptors for
transforming growth factor /3 in human T-cell malignancies. Proc.
Natl .4cad. Sci. U~SA. 91. 6002-6006.
KIKUCHI K. YAMAKAGE A. SMITH EA. LEROY EC AND TROJA-
NOWSKA NI. (1992). Differential modulation of bFGF receptors
by TGF-# in adult skin. scleroderma skin and newborn foreskin
fibroblasts. J. Invest. Dermatol.. 99. '01 -'05.
KINGSLEY DM. (1994). The TGF-# superfamily: newA members. new
receptors. and newv genetic tests offunction in different organisms.
Genes Dev.. 8. 133-146.
LAIHO NI. W'EIS FM. BOY-D FT. IGNOTZ R_ AND MASSAGUE J.
(1991). Responsiveness of transforming growth factor-/3 restored
by complementation between cells defectiv-e in TGF-# receptors I
and II. J. Biol. Chem.. 266, 9108 -9112.
LEOF EB. PROPER JA. GOUSTIN- AS. SHIPLEY GD. DICORLETO PE
AN-D MOSES HL. (1986). Induction of c-sis mRNA and activity
similar to platelet-derived growth factor by transforming growth
factor /3: a proposed model for indirect mitogenesis involving
autocrine activity. Proc. Vatl Acad. Sci. SA. 83, 2453- '457.
LIN HY. WANG X-F. NG-EATON E. WEIN-BERG RA AND LODISH
HF. (1992). Expression cloning of the TGF-# type II receptor. a
functional transmembrane serine threonine kinase. Cell. 68, 775-
785.
LOPEZ-CASILLAS F. CHEIFETZ S. DOODY J. AN-DRES JL. LANE W'S
AND MASSAGUE J. (1991). Structure and expression of the
membrane proteoglIcan. a component of the TGF-/ receptor
sy-stem. Cell. 67. 785- 795.
LOPEZ-CASILLAS F. W'RA-NA JL AN-D MASSAGUE J. (1993).
Betaglycan presents ligand to the TGF-/ signalling receptor.
Cell. 73, 1435- 1444.
MARKOWITZ S. WANG J. MYEROFF L. PARSONS R. SUN L.
LUTTERBAUGH J. FAN- RS. ZBOROW'SKA E. KIN-ZLER KW.
VOGELSTEIN B. BRATTAIN NM AND W'ILLSON JKV. (1995).
Inactivation of the type II TGF-/ receptor in colon cancer cells
w-ith microsatellite instability. Science. 268. 1 336- 1338.
NIASSAGUE J. (1985). Transforming growth factor-/ modulates the
high-affinity receptors for epidermal growth factor and trans-
forming growth factor-alpha. J. Cell Biol.. 100, 1508- 1514.
MASSAGUE J. (1990). The transforming growth factor-/ family.
.4nnu. Rev. Cell Biol.. 6, 597-641.
NIOREN A. ICHIJO H AN-D NMIYAZONO K. (1992). Molecular cloning
and characterization of the human and porcine transforming
growth factor-/ type III receptors. Biochem. BiophYs. Res.
Comm.. 189, 356 -362.
MOSES HL. (1992). TGF-beta regulation of epithelial cell prolifera-
tion. Mtol. Reprod. Dev.. 32. 1 79- 184.
NIOUSTAKAS A. LIN HY. HENNIS YI. PLAMONDON J. O'CONN-OR-
M1CCOU-RT MID AN-D LODISH HF. (1993). The transformina
growth factor fi receptors types I. II and III form hetero-
oligomeric complexes in the presence of ligand. J. Biol. Cheni..
268. 2'215-22218.
NORGAARD P. DAMSTRUP L. RYGAARD K. SPANG-THONMSEN NM
AN-D POULSEN HS. (1994). Growth suppression by transformine
grow-th factor-l1 of human small cell lung cancer cell lines is
associated to expression of the type II receptor. Br. J. Cancer. 69.
802- 808.
N-ORGAARD P. HOUGAARD S. SPANG-THOMSEN- M AND POLLSEN
HS. (1995). Transforming growth factor fl and cancer. Cancer
Treat. Rev.. 21, 367-403.
PARK K. KIM S-J. BANG Y-J. PARK J-G. KINM N-K. ROBERTS AB AN-D
SPORN. MIB (1994). Genetic changes in the transforming growth
factor fi (TGF-fl) type II receptor gene in human eastric cancer
cells: Correlation with sensitivity to growth inhibition by TGF-:.
Proc. Natl .4cad. Sci. U-S_4. 91. 877 -8776.
PETTEN-GILL OS. SORENSON GD. WU-RSTER-HILL D. CURPHEY TJ.
NOLL WAW. CATE CC AN-D MAURER LH. (1980). Isolation and
growth characteristics of continous cell lines from small-cell
carcinoma of the lung. Cancer. 45. 906-9 18.
ROBERTS AB AND SPORN MB. (1990). The transforming growth
factor-fis. In Handhook of Experimental Pharmacology. Peptide
Growth Factors and Their Receptors. Sporn MB and Roberts
AB. (eds.) pp. 419-472. Springer: Heidelberg.
SAMBROOK J. FRITSCH EF AN-D MANIATIS T. (1989). tfolecular
Cloning: .4 Laboratory Mfanual. Cold Spring Harbor Laboratory:
Cold Spring Harbor. N-Y.
SORENSON- GD. PETTENGILL OS. CATE CC AND DELPRETE SA.
(1984). Biomarkers in small cell carcinoma of the lung. In Lung
Cancer. Aisner J (ed.) pp. 203--40. Churchill Livin2stone: New
York.
TEN DIJKE P. YAMASHITA H. ICHIJO H. FRANZEN P. LAIHO M.
MIYAZONO K AND HELDIN- C-H. (1994). Characterization of
type I receptors for transforming growth factor-f and acti-in.
Science. 264, 101- 104.
VXN OBBERGHEN-SCHILLING E. ROCHE NS. FLAN-DERS KC.
SPORN MB AND ROBERTS AB. (1988). Transforming growth
factor fI positively regulates its own expression in normal and
transformed cells. J. Biol. Chem.. 263. 7741 -7746.
WANG X-F. LIN HY. NG-EATON E. DOW-NWAARD J. LODISH HF AND
WEINBERG RA. (1991). Expression cloning and characterization
of the TGF-f type III receptor. Cell. 67. 797-805.
WIN KM. CHARLOTTE F. MALLAT A. CHERQUI D. MARTIN N.
MAVIER P. PREAUX A-NI. DHUMEAUX D AN-D ROSENBAUM J.
(1993). Mitogenic effect of transformin2 growth factor-fl on
human ito cells in culture: evidence for mediation by endogenous
platelet-derived growth factor. Hepatologv. 18. 17- 145.
WRANA JL. ATTISANO L. CARCAMO J. ZENTELLA A. DOODY J.
LAIHO NI. WANG X-F AND NMASSAGUE J. (1992). TGFf signals
through a heteromeric protein kinase complex. Cell. 71. 1003-
1014.
WRANA JL. ATTISA`NO L. A-IESER F. VENTURA-k F AN-D MASSAGUE
J. (1994). Mechanism ofactivation ofthe TGF-fl receptor. Nature.
370, 341-347.
YAMASHITA H. TEN DIJKE P. FRANZEN P. NIIYAZONO K AND
HELDIN C-H. (1994). Formation of hetero-oligomeric complexes
ofty-pe I and ty-pe II receptors for transforming growth factor-f.
J. Biol. Chem.. 269, 2017'-'0178.